Claims for Patent: 11,318,100

Summary for Patent: 11,318,100

Title:	Storage stable sincalide formulations
Abstract:	Disclosed herein are solid compositions that comprise sincalide and are storage stable and which lack a buffer, and optionally, also lack a surfactant/solubilizer, wherein such compositions are storage stable. Also disclosed herein are liquid compositions that comprise sincalide, wherein such compositions are storage stable, and may lack buffer and/or surfactant/solubilizer. Also provided are methods of making and administering the solid or liquid storage stable compositions to a patient in need of, e.g., for the treatment, prevention, and/or diagnosis of gall bladder- and/or pancreatic disorders; or other diagnostic imaging.
Inventor(s):	Srikanth Sundaram
Assignee:	Maia Pharmaceuticals Inc
Application Number:	US17/397,444
Patent Claims:	1. A liquid composition comprising: (a) from 1 to 5 μg/mL of sincalide; (b) from 0.4 to 5 mg/mL of pentetic acid; (c) from 6 to 30 mg/mL of arginine hydrochloride; (d) from 0.8 to 5 mg/mL of L-methionine; (e) from 3 to 15 mg/mL of L-lysine hydrochloride; (f) from 0.008 to 1 mg/mL of sodium metabisulfite; (g) from 34 to 170 mg/mL of mannitol; and (h) a pharmaceutically acceptable carrier, wherein the pH of the liquid composition is 6.5 to 7.5, wherein the liquid composition does not contain phosphate buffer, a surfactant, a solubilizer, polysorbate 20, or polysorbate 80, and wherein the liquid composition maintains total impurities of less than 5% and/or a sincalide level of at least 90% after i) 6 months of storage at 25° C., 65% relative humidity, or ii) 12 months of storage at 2-8° C., when tested by high-performance liquid chromatography. 2. The liquid composition of claim 1, wherein the liquid composition does not contain a buffer having a pKa within one unit of the pH. 3. The liquid composition of claim 2, wherein the liquid composition does not contain a buffer selected from the group consisting of phosphoric acid, citric acid, citrate, sulfosalicylate, acetic acid, acetate, methyl boronic acid, boronate, disodium succinate hexahydrate, lactic acid, lactate, maleic acid, maleate, potassium chloride, benzoic acid, sodium benzoate, carbonic acid, carbonate, bicarbonate, boric acid, sodium borate, sodium chloride, succinic acid, succinate, tartaric acid, tartrate, tris-(hydroxymethyl)aminomethane, N-2-hydroxyethylpiperazine, N′-2-ethanesulfonic acid, CHAPS, and any combination thereof. 4. The liquid composition of claim 1, wherein the liquid composition does not contain a polysorbate. 5. The liquid composition of claim 1, wherein the liquid composition is ready-to-use. 6. The liquid composition of claim 1, wherein the liquid composition comprises: (a) 2.5 μg/mL of sincalide; (b) 1 mg/mL pentetic acid; (c) 15 mg/mL arginine hydrochloride; (d) 2 mg/mL methionine; (e) 7.5 mg/mL lysine hydrochloride; (f) 0.02 mg/mL sodium metabisulfite; and (g) 85 mg/mL mannitol. 7. The liquid composition of claim 1, wherein the liquid composition comprises: (a) 1 μg/mL of sincalide; (b) 0.4 mg/mL pentetic acid; (c) 6 mg/mL arginine hydrochloride; (d) 0.8 mg/mL methionine; (e) 3 mg/mL lysine hydrochloride; (f) 0.008 mg/mL sodium metabisulfite; and (g) 34 mg/mL mannitol. 8. A method comprising administering the liquid composition of claim 1 to the patient. 9. The method of claim 8, further comprising diluting the liquid composition prior to administering it. 10. The method of claim 8, wherein the liquid composition comprises: (a) 2.5 μg/mL of sincalide; (b) 1 mg/mL pentetic acid; (c) 15 mg/mL arginine hydrochloride; (d) 2 mg/mL methionine; (e) 7.5 mg/mL lysine hydrochloride; (f) 0.02 mg/mL sodium metabisulfite; and (g) 85 mg/mL mannitol. 11. The method of claim 8, wherein the liquid composition comprises: (a) 1 μg/mL of sincalide; (b) 0.4 mg/mL pentetic acid; (c) 6 mg/mL arginine hydrochloride; (d) 0.8 mg/mL methionine; (e) 3 mg/mL lysine hydrochloride; (f) 0.008 mg/mL sodium metabisulfite; and (g) 34 mg/mL mannitol. 12. The method of claim 8, wherein the liquid composition does not contain a buffer having a pKa within one unit of the pH. 13. The method of claim 12, wherein the liquid composition does not contain a buffer selected from the group consisting of phosphoric acid, citric acid, citrate, sulfosalicylate, acetic acid, acetate, methyl boronic acid, boronate, disodium succinate hexahydrate, lactic acid, lactate, maleic acid, maleate, potassium chloride, benzoic acid, sodium benzoate, carbonic acid, carbonate, bicarbonate, boric acid, sodium borate, sodium chloride, succinic acid, succinate, tartaric acid, tartrate, tris-(hydroxymethyl)aminomethane, N-2-hydroxyethylpiperazine, N′-2-ethanesulfonic acid, CHAPS, and any combination thereof. 14. The method of claim 8, wherein the liquid composition does not contain a polysorbate. 15. A method of making the liquid composition of claim 1 comprising: mixing: (i) sincalide; (ii) pentetic acid; (iii) arginine hydrochloride; (iv) L-methionine; (v) L-lysine hydrochloride; (vi) sodium metabisulfite; (vii) mannitol; (viii) a pH adjuster; and (ix) water. 16. The method of claim 15, further comprising filling the liquid composition into a vial. 17. The method of claim 15, wherein the liquid composition is a ready-to-use composition. 18. A kit comprising the liquid composition of claim 1 and a vial, wherein the liquid composition has a volume of 1 to 10 mL. 19. A method of making the kit of claim 18 comprising: (a) mixing: (i) sincalide; (ii) pentetic acid; (iii) arginine hydrochloride; (iv) L-methionine; (v) L-lysine hydrochloride; (vi) sodium metabisulfite; (vii) mannitol; (viii) a pH adjuster; (ix) water, wherein mixing generates a liquid composition; and (b) filling the liquid composition into a vial. 20. The method of claim 8, comprising administering the liquid composition in conjunction with a hepatobiliary imaging agent to the patient.